Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.25 Consensus Price Target from Brokerages

Key Points

• Analysts have given Voyager Therapeutics a consensus recommendation of "Buy", with seven analysts rating it as a buy and one issuing a strong buy recommendation.
• The company's stock has seen a 30% increase due to a successful deal with Novartis, and has a 12-month price target of $13.25 from analysts.
• Recent quarterly earnings showed a loss of ($0.57) EPS, falling short of expectations, with revenue of $5.20 million against an anticipated $9.50 million.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has earned a consensus rating of "Buy" from the eight brokerages that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $13.2471.

Separately, Wedbush decreased their price target on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating on the stock in a research report on Thursday, August 7th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new position in shares of Voyager Therapeutics in the fourth quarter worth $29,000. Tower Research Capital LLC TRC increased its position in shares of Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after purchasing an additional 3,077 shares during the period. CWM LLC increased its position in shares of Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after purchasing an additional 9,376 shares during the period. Oxford Asset Management LLP bought a new position in shares of Voyager Therapeutics in the fourth quarter worth $60,000. Finally, Bank of Montreal Can bought a new position in shares of Voyager Therapeutics in the second quarter worth $36,000. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Trading Down 1.2%

VYGR stock traded down $0.04 during trading hours on Friday, hitting $3.36. 203,262 shares of the stock were exchanged, compared to its average volume of 765,882. The firm has a market capitalization of $186.38 million, a P/E ratio of -1.82 and a beta of 0.90. The company has a 50-day simple moving average of $3.29 and a two-hundred day simple moving average of $3.44. Voyager Therapeutics has a 12 month low of $2.64 and a 12 month high of $8.27.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). The firm had revenue of $5.20 million for the quarter, compared to the consensus estimate of $9.50 million. Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. On average, equities research analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.